衰弱对卒中再灌注治疗结局的治疗修饰效应:系统综述与荟萃分析
该系统综述与荟萃分析纳入11项研究、194699例急性缺血性卒中患者,评估卒中前衰弱对再灌注治疗(取栓与溶栓)后 morbidity 和 mortality 的影响。结果显示衰弱与90天死亡率(RR 2.19,95%CI 1.44-3.34)和一年死亡率(RR 2.11,95%CI 1.6-2.78)升高相关,但与症状性颅内出血(RR 1.23,95%CI 0.78-1.96)和改良Rankin评分3-5(RR 2.20,95%CI 0.94-5.16)无显著关联。
要点
- 卒中前衰弱与再灌注治疗后90天及一年死亡率升高相关。
- 衰弱未显著增加症状性颅内出血或卒中后残疾(mRS 3-5)风险。
- 常规评估病前衰弱可能有助于再灌注治疗决策。
核心结论
- 卒中前衰弱与急性缺血性卒中再灌注治疗后不同时间点死亡率升高一致相关,但与症状性颅内出血或卒中后残疾无显著关联。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南检索EMBASE、PubMed、Scopus和Web of Science数据库至2025年8月,纳入11项研究共194699例参与者。
主要发现
- 总体衰弱患病率为37.2%,其中衰弱者72311例、非衰弱者122096例。
- 衰弱与90天死亡率升高相关(RR 2.19,95%CI 1.44-3.34)。
- 衰弱与一年死亡率升高相关(RR 2.11,95%CI 1.6-2.78)。
- 衰弱与症状性颅内出血无显著关联(RR 1.23,95%CI 0.78-1.96)。
- 衰弱与改良Rankin评分3-5无显著关联(RR 2.20,95%CI 0.94-5.16)。
临床怎么用
- 对急性缺血性卒中再灌注治疗决策,可考虑常规评估病前衰弱状态以辅助风险分层。
局限性
- 研究间存在异质性,且需大型多中心前瞻性试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Frailty is common amongst individuals presenting with acute ischaemic stroke (AIS). Not only has frailty been found to have disease-modifying effects in terms of survival and disability after AIS, but it may also exert a treatment-modifying effect in reperfusion therapies. However, studies investigating this to date have frequently been of limited sample size, highlighting the potential for meta-analysis to definitively establish any treatment-modifying effect. OBJECTIVES: We investigate the effect of pre-stroke frailty on morbidity and mortality outcomes following reperfusion treatment (thrombectomy and thrombolysis) for AIS. METHODS: A systematic review was performed according to Preferred Reporting of Items in Systematic Reviews and Meta-Analyses guidelines, via searching the EMBASE, PubMed, Scopus and Web of Science databases up to August 2025. RESULTS: We identified 11 relevant studies with 194,699 participants. Overall, the prevalence of frailty was 37.2% [frail (n = 72,311), non-frail (122,096)]. Frailty was associated with increased 90-day (RR 2.19 [95% CI 1.44-3.34]) and one-year mortality (RR 2.11 [95% CI 1.6-2.78]), but not with symptomatic intracranial haemorrhage (RR 1.23 [95% CI 0.78-1.96]) or modified Rankin score 3-5 (RR 2.20 [0.94-5.16]). CONCLUSIONS: Frailty has a consistent association with mortality at different time points after AIS reperfusion therapies. Despite some study heterogeneity, there is evidence that pre-stroke frailty is associated with increased mortality after treatment, though not with increased risks of symptomatic intracerebral haemorrhage or post-stroke disability. These findings suggest that routine pre-morbid frailty assessment may inform the decision-making process for AIS reperfusion treatment administration. This study highlights the need for large multi-centre prospective trials.
引用
- Varma A, Bhakta S, Dohle E, et al. Treatment-modifying effects of frailty on stroke reperfusion therapy outcomes: a systematic review and meta-analysis. Age Ageing. 2026. PMID: 41965254. doi:10.1093/ageing/afag080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。